Trial Profile
A retrospective study to evaluate cross-reactivity of antibodies in rheumatic patients treated with infliximab (Remicade) towards the biosimilar CT-P13 (Inflectra)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2016
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis; Spondylarthritis
- Focus Pharmacokinetics
- 21 Mar 2016 New trial record
- 10 Mar 2016 Results published in the Annals of the Rheumatic Diseases